Informatie:
Fout:
ID
14498
Beschrijving
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00112853
Link
https://clinicaltrials.gov/show/NCT00112853
Trefwoorden
Versies (1)
- 18-04-16 18-04-16 -
Geüploaded op
18 april 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Adult Acute Megakaryoblastic Leukemia (M7) NCT00112853
Eligibility Adult Acute Megakaryoblastic Leukemia (M7) NCT00112853
- StudyEvent: Eligibility
Similar models
Eligibility Adult Acute Megakaryoblastic Leukemia (M7) NCT00112853
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
AML
Item
adults age with established, pathologically confirmed diagnoses of newly diagnosed aml, including de novo and secondary amls but excluding newly diagnosed acute progranulocytic leukemia (apl, m3), will be considered eligible for study
boolean
C0023467 (UMLS CUI [1])
ecog performance status
Item
ecog performance status 0-2
boolean
C1632812 (UMLS CUI [1])
informed consent
Item
patient must be able to give informed consent
boolean
C0021430 (UMLS CUI [1])
serum creatinine
Item
serum creatinine =< 2.0 mg/dl
boolean
C0201976 (UMLS CUI [1])
sgot and sgpt
Item
sgot and sgpt =< 5 x upper limit normal (uln)
boolean
C1860080 (UMLS CUI [1])
bilirubin
Item
bilirubin =< 2 mg/dl
boolean
C1278039 (UMLS CUI [1])
newly diagnosed aml and hmatopoetic myelodysplasia
Item
newly diagnosed aml, subtypes m0,1,2,4-7 but excluding m3 (apl), including myelodysplasia (mds)-related aml (mds/aml) and treatment-related aml
boolean
C2713368 (UMLS CUI [1])
hydroxyurea
Item
patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for mds (e.g., thalidomide, interferon, cytokines, 5-azacytidine) will be eligible for this trial
boolean
C0020402 (UMLS CUI [1])
R115777 or VP-16
Item
any previous treatment with r115777 or vp-16
boolean
C0393031 (UMLS CUI [1])
C0733688 (UMLS CUI [2])
C0733688 (UMLS CUI [2])
Chemotherapy, immunotherapy, radiation therapy
Item
patients receiving concomitant chemotherapy, radiation therapy or immunotherapy
boolean
C3665472 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C1522449 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
Hyperleukocytic syndrome
Item
hyperleukocytosis with >= 30,000 blasts/ul or rapidly rising blast count with projected doubling time of =< 2 days
boolean
C3805210 (UMLS CUI [1])
adult acute promyelocytic leukemia (M3)
Item
acute progranulocytic leukemia (apl,m3)
boolean
C0279625 (UMLS CUI [1])
cns leukemia
Item
active cns leukemia
boolean
C1332884 (UMLS CUI [1])
Infection
Item
active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible
boolean
C3714514 (UMLS CUI [1])
Life threatening illness
Item
presence of other life-threatening illness
boolean
C3846017 (UMLS CUI [1])
Cognition Disorders or Psychiatric History
Item
patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol
boolean
C0009241 (UMLS CUI [1])
C0748059 (UMLS CUI [2])
C0748059 (UMLS CUI [2])
Anticonvulsants
Item
patients on enzyme-inducing anti-convulsants (e.g., phenytoin, fosphenytoin, phenobarbital, primidone, carbamazepine, oxcarbazepine); patients may be changed to non-enzyme inducing anti-convulsants and stabilized before starting study treatment
boolean
C0003286 (UMLS CUI [1])